Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunologic and inflammatory changes in HIV patients switching to DTG + lamivudine vs B/F/TAF
2018-003458-26Phase 4Completed
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dolutegravir, lamivudine, bictegravir, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Primary: CD8 slope and CD4/CD8 ratio difference between regimens. Started Oct 2020; status: completed.
02
Drugs
dolutegravirlamivudinebictegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2018-003458-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003458-26.